In contrast to the promising efficacy of KRAS G12C inhibitor monotherapy for KRAS G12C mutated advanced NSCLC, previous clinical trials failed to show clear benefit of KRAS G12C inhibitor monotherapy for KRAS G12C mutated CRC (Table 1). This evidence concerns the gene KRAS and non-small cell lung carcinoma.